💚 Health & Wellness
Today's top 5 stories, curated by Daily Direct.
England is facing a worsening measles crisis, with two children dead this year and over 100 new cases reported in the past two weeks alone. London, the East of England, and the West Midlands are the worst-affected regions. The UKHSA is urging parents to ensure children are up to date with their MMR vaccinations as health officials warn the outbreak shows no sign of slowing.
Read article →Growing rat kidneys inside mouse embryos, researchers have demonstrated a promising pathway toward generating transplantable organs using host animals as biological incubators. The technique offers a potential workaround to the chronic donor shortage that leaves millions of kidney disease patients without viable treatment options. With demand for transplants projected to hit 5 million by 2030, advances like this could prove critical to closing the gap between supply and need.
Read article →Metformin, the widely used diabetes drug, cut the risk of developing long COVID by 50% when administered during acute infection, according to new findings from the ACTIV-6 randomized clinical trial. The results confirm earlier research and carry significant weight given metformin's established safety profile and low cost. For the estimated hundreds of millions affected by long COVID globally, an accessible preventive option could be a major turning point.
Read article →The FDA has approved bemotrizinol (BEMT) as a sunscreen ingredient, marking the first new addition to U.S. sunscreen formulations in over 20 years. The broad-spectrum UV filter has been widely used in Europe and Australia for years, suggesting American consumers have long lagged behind in sun protection options. The approval opens the door for more effective sunscreens to hit U.S. shelves in the near future.
Read article →Survodutide, a once-weekly injectable dual agonist targeting both glucagon and GLP-1 receptors, produced significantly greater weight loss in adults with obesity compared to placebo, according to a new study in the New England Journal of Medicine. The findings, presented at the American Diabetes Association's annual meeting, add to growing momentum behind next-generation obesity drugs. If approved, survodutide could expand the treatment landscape beyond existing GLP-1 therapies like semaglutide.
Read article →Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →